JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

Patients with myeloproliferative neoplasms (MPNs) frequently progress to bone marrow failure or acute myeloid leukemia (AML), and mutations in epigenetic regulators such as the metabolic enzyme isocitrate dehydrogenase (IDH) are associated with poor outcomes. Here, we showed that combined expression...

Full description

Bibliographic Details
Main Authors: McKenney, Anna Sophia, Somasundara, Amritha Varshini Hanasoge, Spitzer, Barbara, Intlekofer, Andrew M., Ahn, Jihae, Shank, Kaitlyn, Rapaport, Franck T., Patel, Minal A., Papalexi, Efthymia, Chiu, April, Freinkman, Elizaveta, Akbay, Esra A., Steadman, Mya, Nagaraja, Raj, Yen, Katharine, Teruya-Feldstein, Julie, Wong, Kwok-Kin, Rampal, Raajit, Levine, Ross L., Lau, Allison N., Shihadeh, Alan, Vander Heiden, Matthew G., Thompson, Craig B., Levine, Ross L
Other Authors: Broad Institute of MIT and Harvard
Format: Article
Published: American Society for Clinical Investigation 2018
Online Access:http://hdl.handle.net/1721.1/116943
https://orcid.org/0000-0003-4250-7355
https://orcid.org/0000-0002-6702-4192

Internet

http://hdl.handle.net/1721.1/116943
https://orcid.org/0000-0003-4250-7355
https://orcid.org/0000-0002-6702-4192

Similar Items